Takeda Appoints Serina Fischer As The General Manager For India

Takeda Pharmaceutical Company Limited, a global values-based, R&D-driven biopharmaceutical leader, announced the appointment of Serina Fischer as its General Manager for India operations The appointment is effective as of March 1, 2022. In her new role, Serina will lead the company's business in India, ensuring patient access to the company's highly innovative medicines.

Serina has over 17 years of experience in the biopharmaceutical industry and is an accomplished, dynamic leader with expertise in strategy, sales, marketing, and operations. She joined Takeda in 2017 and has held various leadership roles in its US affiliate.

Commenting on her new role, Serina Fischer said, "I am honoured that the company leadership has entrusted me with this responsibility. With the second-largest population in the world and significant disease burdens in Takeda's chosen therapy areas, India is a vital market from a geographical standpoint for the company. We remain committed to serving patients in India and providing them enhanced access to our highly innovative medicines locally."

Welcoming her on board, Dr. Mahender Nayak, Area Head of ICMEA (India, CIS Countries, Middle East, Turkey, and Africa) for Takeda, said, "At Takeda, we strive to create an exceptional people experience. We aim to create a diverse and inclusive organization to develop, nurture, and accelerate talent by providing exceptional career opportunities to employees worldwide. Serina's appointment as General Manager for India is a part of this process, and I am confident that her unique experience will strengthen our valuable contributions to patients and further enhance our business in India."?

Takeda India is part of Takeda Pharmaceutical Company Limited's group of companies headquartered in Japan. The company focuses on hematology, genetic diseases, immunology, and gastrointestinal portfolios in the country.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

For more information, visit https://www.takeda.com.